




Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas

In collaboration with the American Association of Neuropathologists, Association for Molecular Pathology, and Society for Neuro-Oncology, the College of American Pathologists offers the first evidence-based guideline that comprehensively addresses molecular testing for the diagnosis of diffuse gliomas in the contemporary era.




THE GUIDELINE ANSWERS:

“What ancillary tests are needed to classify diffuse gliomas in order to sufficiently inform the clinical management of patients?”

**3 GOOD PRACTICE
STATEMENTS**

13 RECOMMENDATIONS



**Improve patient care beginning with laboratory testing—
Implement the recommendations to ensure:**

- › optimal diagnosis
- › risk stratification
- › prognosis

Brat DJ, Aldape K, Bridge JA, et al. Molecular biomarker testing for the diagnosis of diffuse gliomas: Guideline from the College of American Pathologists in collaboration with the American Association of Neuropathologists, Association of Molecular Pathology, and Society for Neuro-Oncology. *Arch Pathol Lab Med*. 2022; 146(5): 547–574. doi:10.5858/arpa.2021-0295-CP